Patient characteristics
| Covariate . | Datasets . | All N = 1097, n (%) . | ||
|---|---|---|---|---|
| ALLIANCE N = 127, n (%) . | MER N = 304, n (%) . | MCL-RCS N = 666, n (%) . | ||
| Time to first treatment | ||||
| 0-14 d | 13 (10) | 107 (35) | 180 (27) | 300 (27) |
| 15-60 d | 114 (90) | 197 (65) | 486 (73) | 797 (73) |
| Age at diagnosis, y | ||||
| Median | 60 | 64 | 62 | 63 |
| Range | 29-69 | 32-96 | 29-88 | 29-96 |
| Sex | ||||
| Female | 29 (23) | 69 (23) | 158 (24) | 256 (23) |
| Male | 98 (77) | 235 (77) | 507 (76) | 840 (77) |
| Race | ||||
| White | 116 (96) | 278 (99) | 576 (89) | 970 (92) |
| Black | 4 (3) | 0 (0) | 36 (5) | 40 (4) |
| Others | 1 (1) | 2 (1) | 37 (6) | 40 (4) |
| ECOG PS | ||||
| 0 | 82 (65) | 188 (62) | 331 (58) | 601 (60) |
| 1 | 41 (32) | 86 (28) | 208 (36) | 335 (33) |
| ≥2 | 4 (3) | 30 (10) | 33 (6) | 67 (7) |
| Ann Arbor stage | ||||
| 1-3 | 19 (15) | 49 (16) | 84 (13) | 152 (14) |
| 4 | 108 (85) | 255 (84) | 571 (87) | 934 (86) |
| LDH | ||||
| Normal | 83 (65) | 168 (66) | 263 (56) | 514 (61) |
| Elevated | 44 (35) | 85 (34) | 203 (44) | 332 (39) |
| BM involvement | ||||
| Yes | 106 (83) | 229 (80) | 467 (84) | 802 (83) |
| No | 21 (17) | 56 (20) | 88 (16) | 165 (17) |
| B symptoms | ||||
| Yes | 39 (31) | 62 (21) | 208 (33) | 309 (29) |
| No | 87 (69) | 238 (79) | 413 (67) | 738 (71) |
| MIPI∗ | ||||
| <5.7 | 104 (82) | 85 (34) | 150 (37) | 339 (43) |
| ≥5.7 <6.2 | 15 (12) | 77 (31) | 128 (31) | 220 (28) |
| ≥6.2 | 8 (6) | 88 (35) | 132 (32) | 228 (29) |
| Intensive induction therapy | ||||
| Yes | 127 (100) | 45 (15) | 305 (46) | 477 (44) |
| No | 0 (0) | 259 (85) | 358 (54) | 617 (56) |
| Auto-HCT in CR1 | ||||
| Yes | 104 (82) | 86 (28) | 316 (51) | 506 (48) |
| No | 23 (18) | 218 (72) | 310 (49) | 551 (52) |
| Ki-67 percentage | ||||
| ≤30% | 62 (84) | - | 162 (52) | 224 (58) |
| >30% | 12 (16) | - | 149 (48) | 161 (42) |
| Median f/up in years | 8.5 | 8.0 | 3.5 | 5.0 |
| Covariate . | Datasets . | All N = 1097, n (%) . | ||
|---|---|---|---|---|
| ALLIANCE N = 127, n (%) . | MER N = 304, n (%) . | MCL-RCS N = 666, n (%) . | ||
| Time to first treatment | ||||
| 0-14 d | 13 (10) | 107 (35) | 180 (27) | 300 (27) |
| 15-60 d | 114 (90) | 197 (65) | 486 (73) | 797 (73) |
| Age at diagnosis, y | ||||
| Median | 60 | 64 | 62 | 63 |
| Range | 29-69 | 32-96 | 29-88 | 29-96 |
| Sex | ||||
| Female | 29 (23) | 69 (23) | 158 (24) | 256 (23) |
| Male | 98 (77) | 235 (77) | 507 (76) | 840 (77) |
| Race | ||||
| White | 116 (96) | 278 (99) | 576 (89) | 970 (92) |
| Black | 4 (3) | 0 (0) | 36 (5) | 40 (4) |
| Others | 1 (1) | 2 (1) | 37 (6) | 40 (4) |
| ECOG PS | ||||
| 0 | 82 (65) | 188 (62) | 331 (58) | 601 (60) |
| 1 | 41 (32) | 86 (28) | 208 (36) | 335 (33) |
| ≥2 | 4 (3) | 30 (10) | 33 (6) | 67 (7) |
| Ann Arbor stage | ||||
| 1-3 | 19 (15) | 49 (16) | 84 (13) | 152 (14) |
| 4 | 108 (85) | 255 (84) | 571 (87) | 934 (86) |
| LDH | ||||
| Normal | 83 (65) | 168 (66) | 263 (56) | 514 (61) |
| Elevated | 44 (35) | 85 (34) | 203 (44) | 332 (39) |
| BM involvement | ||||
| Yes | 106 (83) | 229 (80) | 467 (84) | 802 (83) |
| No | 21 (17) | 56 (20) | 88 (16) | 165 (17) |
| B symptoms | ||||
| Yes | 39 (31) | 62 (21) | 208 (33) | 309 (29) |
| No | 87 (69) | 238 (79) | 413 (67) | 738 (71) |
| MIPI∗ | ||||
| <5.7 | 104 (82) | 85 (34) | 150 (37) | 339 (43) |
| ≥5.7 <6.2 | 15 (12) | 77 (31) | 128 (31) | 220 (28) |
| ≥6.2 | 8 (6) | 88 (35) | 132 (32) | 228 (29) |
| Intensive induction therapy | ||||
| Yes | 127 (100) | 45 (15) | 305 (46) | 477 (44) |
| No | 0 (0) | 259 (85) | 358 (54) | 617 (56) |
| Auto-HCT in CR1 | ||||
| Yes | 104 (82) | 86 (28) | 316 (51) | 506 (48) |
| No | 23 (18) | 218 (72) | 310 (49) | 551 (52) |
| Ki-67 percentage | ||||
| ≤30% | 62 (84) | - | 162 (52) | 224 (58) |
| >30% | 12 (16) | - | 149 (48) | 161 (42) |
| Median f/up in years | 8.5 | 8.0 | 3.5 | 5.0 |
Of note, the data on blastoid histology were only available in the MCL-RCS data set. Among the patients with available data (n = 534), only 15% (n = 81) had blastoid histology.
auto-HCT, autologous hematopoietic cell transplantation; CR1, first complete remission; f/up, follow-up.
The MIPI score from the ALLIANCE data set was generated from the integer value of 0 to 8 giving us the distribution as outlined in the Table. This is different from what is reported in the ALLIANCE publications which used 0 to 3, 4 to 5, and 6 to 8 as low, intermediate, and high risk, respectively.